Department of Influenza and Other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran.
Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
J Biomol Struct Dyn. 2024 Sep;42(15):7730-7746. doi: 10.1080/07391102.2023.2241554. Epub 2023 Aug 8.
Antiviral drugs are currently used to prevent or treat viral infections like influenza A Virus (IAV). Nonetheless, annual genetic mutations of influenza viruses make them resistant to efficient treatment by current medications. Antiviral peptides have recently attracted researchers' attention and can potentially supplant the current medications. This study aimed to design peptides against IAV propagation. For this purpose, P2 and P3 peptides were computationally designed based on the HCDR3 region of the C05 antibody (a monoclonal antibody that neutralizes influenza HA protein and inhibits the virus attachment). The synthesized peptides were tested against the influenza A virus (A/Puerto Rico/8/34 (H1N1)) , and the most efficient peptide was selected for experiments. It was shown that the designed peptide shows much more prophylactic and therapeutic effects against the virus. These findings demonstrated that the designed peptide can control the virus infection without any cytotoxicity effect. Antiviral peptide design is acknowledged as a critical tactic to manage viral infections by preventing viral binding to the host cells.Communicated by Ramaswamy H. Sarma.
抗病毒药物目前被用于预防或治疗流感病毒（IAV）等病毒感染。然而，流感病毒每年的遗传突变使其对现有药物的治疗产生耐药性。抗病毒肽最近引起了研究人员的关注，并有可能取代现有药物。本研究旨在设计针对 IAV 传播的肽。为此，根据 C05 抗体（一种中和流感 HA 蛋白并抑制病毒附着的单克隆抗体）的 HCDR3 区域，计算设计了 P2 和 P3 肽。合成的肽针对流感 A 病毒（A/Puerto Rico/8/34（H1N1））进行了测试，选择了最有效的肽进行实验。结果表明，设计的肽对病毒显示出更强的预防和治疗效果。这些发现表明，设计的肽可以在没有任何细胞毒性作用的情况下控制病毒感染。抗病毒肽设计被认为是通过防止病毒与宿主细胞结合来控制病毒感染的关键策略。由 Ramaswamy H. Sarma 传达。
